At the end of 2007 the FAMHP initiated a programme for specific monitoring of new medicines (“black triangle” – symbol included in the BCFI-CBIP annotated drugs formulary – Gecommentarieerd Geneesmiddelenrepertorium – Répertoire Commenté des Médicaments) with the aim of encouraging healthcare professionals to report adverse effects of medicines with a new active substance to the FAMHP.
At the end of 2007 the FAMHP initiated a programme for specific monitoring of new medicines (“black triangle” – symbol included in the BCFI-CBIP annotated drugs formulary – Gecommentarieerd Geneesmiddelenrepertorium – Répertoire Commenté des Médicaments) with the aim of encouraging healthcare professionals to report adverse effects of medicines with a new active substance to the FAMHP.
